NDC 0002-3977

RETEVMO

Selpercatinib

RETEVMO is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Selpercatinib.

• Product ID: 0002-3977_1ebfa429-955a-4e8b-a1bf-b77f5e790780
• NDC: 0002-3977
• Product Type: Human Prescription Drug
• Proprietary Name: RETEVMO
• Generic Name: Selpercatinib
• Dosage Form: Capsule
• Route of Administration: ORAL
• Marketing Start Date: 2020-05-08
• Marketing Category: NDA / NDA
• Application Number: NDA213246
• Labeler Name: Eli Lilly and Company
• Substance Name: SELPERCATINIB
• Active Ingredient Strength: 40 mg/1
• Pharm Classes: Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0002-3977-60

60 CAPSULE in 1 BOTTLE (0002-3977-60)

• Marketing Start Date: 2020-05-08
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0002-3977-60 [00002397760]

RETEVMO CAPSULE

• Marketing Category: NDA
• Application Number: NDA213246
• Product Type: HUMAN PRESCRIPTION DRUG
• Marketing Start Date: 2020-05-08

Drug Details

NDC Crossover Matching brand name "RETEVMO" or generic name "Selpercatinib"

NDC	Brand Name	Generic Name
0002-2980	RETEVMO	selpercatinib
0002-3977	RETEVMO	selpercatinib